Lobbying

Blood Cancer United's latest lobbying report covers Q2 2026, at $590K. The four quarters Q4 2025–Q3 2026 total $1.3M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.

Blood Cancer United

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$1.3M
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Blood Cancer United lobbying by quarter
Blood Cancer United lobbying by quarter
QuarterAmountReports
Q4 2022$140K1
Q1 2023$130K1
Q2 2023$480K1
Q3 2023$150K1
Q4 2023$440K1
Q1 2024$100K1
Q2 2024$570K1
Q3 2024$160K1
Q4 2024$180K1
Q1 2025$130K1
Q2 2025$1.1M1
Q3 2025$140K1
Q4 2025$610K1
Q1 2026$110K1
Q2 2026$590K1
Q3 2026$00

By issue

  • Budget and appropriations$1.2M · 15 reports
  • Health issues$1.2M · 15 reports
  • Medicare and Medicaid$1.2M · 15 reports
  • Medical research and clinical labs$966K · 12 reports
  • Taxation$301K · 4 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES15 reports
  • SENATE15 reports
  • Health & Human Services, Dept of (HHS)11 reports
  • Centers For Medicare and Medicaid Services (CMS)10 reports
  • Natl Institutes of Health (NIH)10 reports
  • White House Office9 reports
  • Food & Drug Administration (FDA)7 reports
  • Treasury, Dept of5 reports
  • Labor, Dept of (DOL)4 reports
  • Office of Management & Budget (OMB)1 reports

Firms it paid

Firm
In-houseBlood Cancer United$5M15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2In-house$590K
04/20for Q1In-house$110K
01/20for Q4 2025In-house$610K
25/10/23for Q3 2025In-house$140K
25/07/21for Q2 2025In-house$1.1M
25/04/22for Q1 2025In-house$130K
25/02/03for Q4 2024In-house$180K
24/10/21for Q3 2024In-house$160K
24/07/22for Q2 2024In-house$570K
24/04/30for Q1 2024In-house$100K
24/02/05for Q4 2023In-house$440K
23/10/23for Q3 2023In-house$150K
23/07/20for Q2 2023In-house$480K
23/04/14for Q1 2023In-house$130K
23/01/20for Q4 2022In-house$140K